Phase II Study Of Herceptin And Exemestane For Treatment Of Postmenopausal Women With Metastatic Hormone-Responsive, HER2/NEU Positive Breast Cancer
- Determine the efficacy of exemestane and trastuzumab (Herceptin), in terms of response
rate and time to progression, in postmenopausal women with metastatic or locally
advanced hormone-responsive, HER2/neu positive breast cancer.
- Determine the toxicity of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive trastuzumab (Herceptin) IV over 30-90 minutes on day 1 and oral exemestane
once daily. Treatment repeats every 3 weeks in the absence of disease progression or
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 18-60 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Virginia G. Kaklamani, MD
Robert H. Lurie Cancer Center
United States: Federal Government